An expert discusses how rilzabrutinib uniquely improves quality-of-life metrics, including fatigue and women’s health domains, which previous immune thrombocytopenia (ITP) therapies failed to address ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results